KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash & Current Investments (2016 - 2026)

Alnylam Pharmaceuticals filings provide 18 years of Cash & Current Investments readings, the most recent being $3.0 billion for Q1 2026.

  • Quarterly Cash & Current Investments rose 193.05% to $3.0 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.0 billion through Mar 2026, up 193.05% year-over-year, with the annual reading at $2.9 billion for FY2025, 197.75% up from the prior year.
  • Cash & Current Investments hit $3.0 billion in Q1 2026 for Alnylam Pharmaceuticals, up from $2.9 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $3.0 billion in Q1 2026 and bottomed at $685.1 million in Q2 2023.
  • Average Cash & Current Investments over 5 years is $2.0 billion, with a median of $2.2 billion recorded in 2022.
  • The largest annual shift saw Cash & Current Investments crashed 67.06% in 2023 before it soared 281.69% in 2024.
  • Alnylam Pharmaceuticals' Cash & Current Investments stood at $896.7 million in 2022, then surged by 170.8% to $2.4 billion in 2023, then plummeted by 59.77% to $976.8 million in 2024, then soared by 197.75% to $2.9 billion in 2025, then rose by 3.46% to $3.0 billion in 2026.
  • Per Business Quant, the three most recent readings for ALNY's Cash & Current Investments are $3.0 billion (Q1 2026), $2.9 billion (Q4 2025), and $2.7 billion (Q3 2025).